Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Interindividual variability in anatomical and physiological properties results in significant differences in drug pharmacokinetics. The consideration of such pharmacokinetic variability supports optimal drug efficacy and safety for each single individual, e.g. by identification of individual-specific dosings. One clear objective in clinical drug development is therefore a thorough characterization of the physiological sources of interindividual variability. In this work, we present a Bayesian population physiologically-based pharmacokinetic (PBPK) approach for the mechanistically and physiologically realistic identification of interindividual variability. The consideration of a generic and highly detailed mechanistic PBPK model structure enables the integration of large amounts of prior physiological knowledge, which is then updated with new experimental data in a Bayesian framework. A covariate model integrates known relationships of physiological parameters to age, gender and body height. We further provide a framework for estimation of the a posteriori parameter dependency structure at the population level. The approach is demonstrated considering a cohort of healthy individuals and theophylline as an application example. The variability and co-variability of physiological parameters are specified within the population; respectively. Significant correlations are identified between population parameters and are applied for individual- and population-specific visual predictive checks of the pharmacokinetic behavior, which leads to improved results compared to present population approaches. In the future, the integration of a generic PBPK model into an hierarchical approach allows for extrapolations to other populations or drugs, while the Bayesian paradigm allows for an iterative application of the approach and thereby a continuous updating of physiological knowledge with new data. This will facilitate decision making e.g. from preclinical to clinical development or extrapolation of PK behavior from healthy to clinically significant populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gelman, A. (2006) · Bayesian Analysis · doi:10.1214/06-ba117a · Cited by 4,050
An introduction to MCMC for machine learning.
Andrieu, C., de Freitas, N., Doucet, A., & Jordan, M. I. (2003) · Machine Learning · doi:10.1023/a:1020281327116 · Cited by 2,451
Riemann manifold langevin and hamiltonian monte carlo methods
Girolami, M., & Calderhead, B. (2011) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2010.00765.x · Cited by 1,473
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions
Gelman, A., Bois, F., & Jiang, J. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476708 · Cited by 353
Eissing, T. (2011) · Frontiers in Physiology · doi:10.3389/fphys.2011.00004 · Cited by 204
Willmann, S., Lippert, J., & Schmitt, W. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.159 · Cited by 140 · cited 1×
“PK-Sim 1 and MoBi 1 have both been explained in detail before [12, 28, 44, 45].”
A Mechanistic, Model‐Based Approach to Safety Assessment in Clinical Development
Lippert, J., Brosch, M., von Kampen, O., Meyer, M., Siegmund, H. ‐., Schafmayer, C., Becker, T., Laffert, B., Görlitz, L., Schreiber, S., et al. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.14 · Cited by 43 · cited 1×
“On the one hand, a therapeutic effect of the drug is desired to be achieved for all patients; on the other hand too high concentrations have to be avoided to reduce adverse events [1, 2].”
Self-citation
Cited by
Darwich, A. S., Ogungbenro, K., Vinks, A. A., Powell, J. R., Reny, J., Marsousi, N., Daali, Y., Fairman, D., Cook, J., Lesko, L. J., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.659 · Cited by 279
Jamei, M. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0059-9 · Cited by 244
“To address this, among other methods, the use of global and/or local sensitivity analysis [21] and the Bayesian framework [19] are proposed.”
MethodHelmlinger, G., Al-Huniti, N., Aksenov, S., Peskov, K., Hallow, K. M., Chu, L., Boulton, D., Eriksson, U., Hamrén, B., Lambert, C., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.028 · Cited by 33
Ratier, A., Casas, M., Grazuleviciene, R., Slama, R., Småstuen Haug, L., Thomsen, C., Vafeiadi, M., Wright, J., Zeman, F. A., Vrijheid, M., et al. (2024) · Environment International · doi:10.1016/j.envint.2024.108621 · Cited by 16
Metadata
- Authors
- Krauss, M., Tappe, K., Schuppert, A., Kuepfer, L., & Goerlitz, L.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-02
- Volume
- 10
- Issue
- 10
- Pages
- e0139423
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2180009825
- Cited by
- 51
- References
- 8
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. https://app.cochat.ai/papers/10.1371/journal.pone.0139423
- The paper
- Krauss, M., Tappe, K., Schuppert, A., Kuepfer, L., & Goerlitz, L. (2015). Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. PLOS ONE. https://doi.org/10.1371/journal.pone.0139423
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.